Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 21:01:42 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Medivir - Liver Project Getting Ready to Deliver

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Medivir - Liver Project Getting Ready to Deliver

2022-03-07 10:00:00

Redeye still believes that, with the Medivir share trading at the same levels as a year ago, the stock market has not fully appreciated the company’s progress. We see three main reasons to invest in Medivir: fostroxacitabine bralpamide, its partnered projects, and its non-licensed projects (to which we attach optional value). Its aim with fostroxacitabine is to bring chemotherapy to advanced liver cancer, while Medivir’s flagship partnered candidate birinapant holds a licensing deal worth up to USD 350m plus royalties.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/